Artificial heart survived for four days under mechanical support but did not recover from the complications of the cardiac arrest; finally, the pump was discontinued, and the patient died. On April 21, 1966, Michael DeBakey and Liotta implanted the first clinical LVAD in a paracorporeal position (where the external pump rests at the side of the patient) at The Methodist Hospital in Houston, in a patient experiencing cardiogenic shock after heart surgery. The patient developed neurological and pulmonary complications and died after few days of LVAD mechanical support. In October 1966, DeBakey and Liotta implanted the paracorporeal Liotta-DeBakey LVAD in a new
Human artificial chromosome artificial chromosome vectors. The first is to create a small minichromosome by altering a natural human chromosome. This is accomplished by truncating the natural chromosome, followed by the introduction of unique genetic material via the Cre-Lox system of recombination. The second method involves the literal creation of a novel chromosome "de novo". Progress regarding "de novo" HAC formation has been limited, as many large genomic fragments will not successfully integrate into "de novo" vectors. Another factor limiting "de novo" vector formation is limited knowledge of what elements are required for construction, specifically centromeric sequences. A 2009 study has shown additional